Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/260 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11409130
PMID: | 11409130
LR: | 20061115
CED: | 20010618
DCO: | 20011204
Autoren: | Thie NM; Prasad NG; Major PW
Titel: | Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial.
Quelle: | The Journal of rheumatology; VOL: 28 (6); p. 1347-55 /200106/
PM: | Print
SU: | IM
Sprache: | English
CY: | Canada
JID: | 7501984
ISSN: | 0315-162X
CO: | JRHUA9
Institution: | Orofacial Pain Clinic, Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
DT: | Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*administration & dosage; GLUCOSAMINE/adverse effects; HUMANS; IBUPROFEN/*administration & dosage; IBUPROFEN/adverse effects; MALE; MIDDLE AGED; OSTEOARTHRITIS/*drug therapy; PAIN/drug therapy; TEMPOROMANDIBULAR JOINT/*; TREATMENT OUTCOME
CTG: | ERWACHSENER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*Verabreichung & Dosierung; GLUCOSAMIN/unerwünschte Nebenwirkungen; MENSCH; IBUPROFEN/*Verabreichung & Dosierung; IBUPROFEN/unerwünschte Nebenwirkungen; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Arzneimitteltherapie; SCHMERZEN/Arzneimitteltherapie; TEMPOROMANDIBULARGELENK/*; BEHANDLUNGSERGEBNIS
TE: | Anti-Inflammatory Agents, Non-Steroidal; Ibuprofen/15687-27-1; Glucosamine/3416-24-8
CR: | 15687-27-1; 3416-24-8
AB: | OBJECTIVE: To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA). METHODS: Forty women and 5 men received either GS (500 mg tid) or ibuprofen (400 mg tid) for 90 days in a randomized double blind study. Assessment: TMJ pain with function, pain-free, and voluntary maximum mouth opening, Brief Pain Inventory (BPI) questionnaire and masticatory muscle tenderness were performed after a one week washout and at Day 90. Acetaminophen (500 mg) dispensed for breakthrough pain was counted every 30 days to Day 120. RESULTS: In total, 176 adults were interviewed, 45 (26%) qualified, 39 (87%) completed the study (21 GS, 18 ibuprofen). Four discontinued due to stomach upset (3 ibuprofen, one GS), one due to dizziness (GS), one due to inadequate pain control (ibuprofen). Within-group analysis revealed significant improvement compared to baseline of all variables in both treatment groups but no change in acetaminophen used. Fifteen GS (71%) and 11 ibuprofen (61%) improved, with positive clinical response taken as a 20% decrease in primary outcome (TMJ pain with function). The number of patients with positive clinical response was not statistically different between groups (p = 0.73). Between-group comparison revealed that patients taking GS had a significantly greater decrease in TMJ pain with function, effect of pain, and acetaminophen used between Day 90 and 120 compared with patients taking ibuprofen. CONCLUSION: GS and ibuprofen reduce pain levels in patients with TMJ degenerative joint disease. In the subgroup that met the initial efficacy criteria, GS had a significantly greater influence in reducing pain produced during function and effect of pain with daily activities. GS has a carryover effect.

» Volltext »
» Fenster schließen »